Internal Reference Number: FOI_8560
Date Request Received: 07/04/2025 00:00:00
Date Request Replied To: 10/04/2025 00:00:00
This response was sent via: By Email
Request Summary: treatment of Haemophilia A
Request Category: Researcher
| Question Number 1: I am researching the incidence and treatment of Haemophilia A across the UK. I would greatly appreciate if you could answer to the following questions. How many haemophilia A patients are registered with your centre, and how many of these patients are classified as exhibiting mild, moderate, or severe disease. | |
| Answer To Question 1: Question 1: A total of 34 Haemophilia A patients are registered to Salisbury centre, broken down by severity as follows:- 26 - mild <5 - moderate 5 - severe | |
| Question Number 2: In the last three months, how many Haemophilia A patients, including on-demand patients, have been treated with the following products? • Altuvoct • Advate • Adynovi • Elocta • Esperoct • Factor Eight Inhibitor Bypass Activity (FEIBA) • Hemlibra (Emicizumab) - Standalone • Hemlibra (Emicizumab) in combination with any Factor VIII • NovoEight • NovoSeven RT • Nuwiq • Obizur • Refacto AF • Any other products • Hympavzi (Marstacimab) • CEVENFACTA | |
| Answer To Question 2: Question 2 : In the last 3 months : <5 patients have been treated with Advate <5 patients have been treated with Elocta | |
| Question Number 3: For patients treated with Advate in the last three months, please provide: • The number of haemophilia A patients treated prophylactically • The number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds) | |
| Answer To Question 3: Question 3 : <5 Advate patients were treated for 'any other reason (e.g. Surgery, on-demand, breakthrough bleeds). | |
| Question Number 4: In the last three months, how many patients were treated with the following products for severe Haemophila A ONLY? • Altuvoct • Advate • Adynovi • Elocta • Esperoct • Factor Eight Inhibitor Bypass Activity (FEIBA) • Hemlibra (Emicizumab) - Standalone • Hemlibra (Emicizumab) in combination with any Factor VIII • NovoEight • NovoSeven RT • Nuwiq • Obizur • Refacto AF • Any other products • Hympavzi (Marstacimab) • CEVENFACTA | |
| Answer To Question 4: Question 4 : <5 patients with severe haemophilia have been treated in the last 3 months. | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
